Evaluation of effect of the primary particle size on compactibility of spray-dried lactoses

Spray-dried lactose is one of the most used filler-binders in direct compaction of tablets. Spray-dried lactose is produced by spray-drying a suspension of α-lactose monohydrate crystals in a saturated aqueous solution of lactoses. The resulting product is composed of spherical particles, containing 80-85% crystals of α-lactose monohydrate (primary particles) and 15-20% amorphous lactose The compactibility of two commercial spray-dried lactoses, Pharmatose® DCL 11 (DCL11), prepared from α-lactose monohydrate with a median primary particle size of 34 µm and a new product, Pharmatose® DCL 14 (DCL14), prepared from 20 µm primary particles, were investigated

Oral dosage forms of a therapeutically active acid-labile salt and methods and uses related thereto.

The invention relates to the field of oral drug delivery and more in particular, to oral dosage forms for delivery of a high dose of a therapeutically active acid-labile salt, such as sodium thiosulfate (STS). Provided is a pharmaceutical oral dosage form for controlled delivery of an acid-labile salt, the dosage form comprising a core comprising the acid-labile salt in a polymer matrix comprising a combination of (i) a pH- sensitive hydrophilic methacrylic acid— methyl methacrylate copolymer and (ii) a carbomer, wherein the acid-labile salt makes up at least 50wt% of the core; and wherein the outer surface of the core is provided with an enteric coating layer

Oral dosage forms of a therapeutically active acid-labile salt and methods and uses related thereto.

The invention relates to the field of oral drug delivery and more in particular, to oral dosage forms for delivery of a high dose of a therapeutically active acid-labile salt, such as sodium thiosulfate (STS). Provided is a pharmaceutical oral dosage form for controlled delivery of an acid-labile salt, the dosage form comprising a core comprising the acid-labile salt in a polymer matrix comprising a combination of (i) a pH- sensitive hydrophilic methacrylic acid— methyl methacrylate copolymer and (ii) a carbomer, wherein the acid-labile salt makes up at least 50wt% of the core; and wherein the outer surface of the core is provided with an enteric coating layer

Gastro-retentive drug delivery system

The invention relates to floating drug delivery systems(FDDS) that provide solutions to the particular problems often encountered with floating drug delivery systems described in the art. On such generally recognized problem is the vulnerability of the systems, especially damage to the gas-filled compartment making it accessible to water so as to impair its buoyancy, ultimately resulting in insufficient gastric residence time. The invention, in an aspect, provides a self-repairing FDDS that maintains its floating capacity after damaging. The floating drug delivery systems of the invention, furthermore,allow for incorporation of high loads of active ingredients. The floating drug delivery systems can be designed in such a way that release of active ingredient from the system occurs entirely independent from the pH of the fluid surrounding the system. Furthermore, the procedure of manufacturing the floating drug delivery system of the invention is simple and straightforward, and therefore economically attractive

Gastro-retentive drug delivery system

The invention relates to floating drug delivery systems(FDDS) that provide solutions to the particular problems often encountered with floating drug delivery systems described in the art. On such generally recognized problem is the vulnerability of the systems, especially damage to the gas-filled compartment making it accessible to water so as to impair its buoyancy, ultimately resulting in insufficient gastric residence time. The invention, in an aspect, provides a self-repairing FDDS that maintains its floating capacity after damaging. The floating drug delivery systems of the invention, furthermore,allow for incorporation of high loads of active ingredients. The floating drug delivery systems can be designed in such a way that release of active ingredient from the system occurs entirely independent from the pH of the fluid surrounding the system. Furthermore, the procedure of manufacturing the floating drug delivery system of the invention is simple and straightforward, and therefore economically attractive